Pacific Biosciences of California Inc
NASDAQ:PACB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pacific Biosciences of California Inc
NASDAQ:PACB
|
US |
|
Bio Path Holdings Inc
NASDAQ:BPTH
|
US |
|
P
|
PNE Industries Ltd
SGX:BDA
|
SG |
|
F
|
Forise International Ltd
SGX:8A1
|
SG |
|
Texas Capital Bancshares Inc
NASDAQ:TCBI
|
US |
|
C
|
ChannelAdvisor Corp
F:CDL
|
US |
|
Adacel Technologies Ltd
ASX:ADA
|
AU |
|
C
|
China Vast Industrial Urban Development Company Ltd
HKEX:6166
|
HK |
|
J
|
Jeju Semiconductor Corp
KOSDAQ:080220
|
KR |
|
DSV A/S
F:DS81
|
DK |
|
Baylin Technologies Inc
TSX:BYL
|
CA |
|
Element Fleet Management Corp
TSX:EFN
|
CA |
|
B
|
Binah Capital Group Inc
NASDAQ:BCG
|
US |
|
S
|
Semapa Sociedade de Investimento e Gestao SGPS SA
ELI:SEM
|
PT |
|
L
|
Lovina Beach Brewery Tbk PT
IDX:STRK
|
ID |
|
I
|
IAA Inc
F:3NI
|
US |
Wall Street
Price Targets
PACB Price Targets Summary
Pacific Biosciences of California Inc
According to Wall Street analysts, the average 1-year price target for
PACB
is 2.3 USD
with a low forecast of 1.01 USD and a high forecast of 3.15 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is PACB's stock price target?
Price Target
2.3
USD
According to Wall Street analysts, the average 1-year price target for
PACB
is 2.3 USD
with a low forecast of 1.01 USD and a high forecast of 3.15 USD.
What is Pacific Biosciences of California Inc's Revenue forecast?
Projected CAGR
13%
For the last 14 years the
compound annual growth rate for
Pacific Biosciences of California Inc's revenue is
12%.
The projected
CAGR
for the next 3 years is
13%.
